Noncovalent SUMO-interaction motifs in HIV integrase play important roles in SUMOylation, cofactor binding, and virus replication
HIV integrase (IN) and its cellular cofactors, including lens-epithelium-derived growth factor (LEDGF/p75), Ku70, p300, and Rad52, are subject to small ubiquitin-like modifier (SUMO) modification. In addition to covalent SUMOylation, SUMO paralogs can also noncovalently bind proteins through SUMO-interacting motifs (SIMs). However, little is known about whether HIV IN contains SIMs and the roles of these motifs.
We searched for the amino acid sequence of HIV IN and investigated three putative SIMs of IN: SIM1 72VILV75, SIM2 200IVDI203 and SIM3 257IKVV260. Our mutational analysis showed that 200IVDI203 and 257IKVV260 are two bona fide SIMs that mediate IN-SUMO noncovalent interactions. Additionally, a cell-based SUMOylation assay revealed that IN SIMs negatively regulate the SUMOylation of IN, as well as the interaction between IN and SUMO E2 conjugation enzyme Ubc9. Conversely, IN SIMs are required for its interactions with LEDGF/p75 but not with Ku70. Furthermore, our study reveals that SIM2 and SIM3 are required for the nuclear localization of IN. Finally, we investigated the impact of IN SIM2 and SIM3 on HIV single cycle replication in CD4+ C8166 T cells, and the results showed that viruses carrying IN SIM mutants are replication defective at the steps of the early viral life cycle, including reverse transcription, nuclear import and integration.
Our data suggested that the INSIM-SUMO interaction constitutes a new regulatory mechanism of IN functions and might be important for HIV-1 replication.
KeywordsHuman immunodeficiency virus (HIV) Integrase (IN) SUMOylation SUMO-interacting motifs (SIMs) LEDGF/p75 Protein-protein interaction Nuclear localization HIV replication
Catalytic core domain
Lens-epithelium-derived growth factor
Promyelocytic leukemia protein
Small ubiquitin-like modifier
HIV integrase (IN) is a key viral enzyme that catalyzes the integration of viral DNA into the host genome in all retroviruses. HIV-1 IN also functions in other key steps during the viral life cycle, including reverse transcription, nuclear import of the preintegration complex (PIC) and postintegration steps, such as viral protein expression, transcription, packaging and processing [1, 2, 3, 4]. Similar to all retroviral INs, HIV-1 IN contains three canonical domains: an N-terminal HH-CC zinc-binding domain, a catalytic core domain (CCD) and a C-terminal DNA-binding domain, each with different individual functions. Full-length IN is a multimeric enzyme that functions as a tetramer . IN undergoes multiple posttranslational modifications (PTMs) (e.g., ubiquitination, SUMOylation, acetylation and phosphorylation), which have been shown to play versatile roles in the functions of IN and HIV-1 viral replication [6, 7, 8, 9]. The SUMOylation of IN has been published earlier . However, much is still unknown about the physiological mechanisms of this modification.
Small ubiquitin-like modifier (SUMO) proteins are ~ 10 kD in size, and there are four subtypes (SUMO 1–4) in mammals, which are conserved among all eukaryotic cells . SUMO 1, 2 and 3 are ubiquitous in cells, whereas SUMO4 is only expressed in certain tissues and organs [10, 11]. While SUMO2 and SUMO3 are 96% identical to each other, SUMO1 only shares 45% amino acid identity with SUMO2/3. SUMOylation is accomplished by a series of enzyme-catalyzed reactions . Three enzymes are required for all SUMO modification pathways, including SUMO activating enzyme E1 (a heterodimer of Aos1 and Uba2), the unique E2 conjugating enzyme Ubc9 and a number of different E3 ligases, such as PIAS and RanBP2 . In a previous study, Ubc9 was shown to interact with HIV-1 IN, and SUMO2/3 and Ubc9 negatively regulate the HIV-1 integration step . Similar to ubiquitination, the substrate proteins can be poly-SUMOylated or mono-SUMOylated at single or multiple Lys targets. The outcomes of SUMO modification vary greatly from protein stability, cytosolic-nuclear translocation, and antagonizing other posttranslational modifications to transcriptional regulation .
During the SUMOylation, SUMOs are covalently conjugated to protein substrates through canonical four-amino-acid SUMO conjugation sites ψ-K-x-D/E (where ψ is a hydrophobic amino acid and x is any amino acid). HIV-1 IN was demonstrated to contain three SUMOylation sites (45LKGE, 135IKQE and 243WKQE) at three Lys residues (K46, K136 and K244), and the impairment of IN SUMOylation correlated with an early replication defect. Even though the mechanism underlying IN SUMOylation is not clear, it was hypothesized that SUMOylation might regulate the proximity between IN and its co-factors, which is indispensable for efficient viral replication . IN has been shown to interact with multiple host proteins. Interestingly, a number of IN-interacting proteins, such as LEDGF/p75, Ku70, p300 and Rad52, are also SUMOylated [15, 16, 17, 18]. LEDGF/p75 is one of the most important cofactors for IN . Previous studies have shown that LEDGF/p75, as an IN-interacting protein, carried out multiple functions during HIV infection, including tethering IN to transcriptionally active regions of host chromosomes, enhancing the enzymatic activity of IN, stabilizing IN subunit-subunit interactions and promoting IN tetramerization and protecting IN from proteasomal degradation [20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33]. Interestingly, a previous study revealed that SUMOylation–defective IN mutants still retained LEDGF/p75 binding ability , and HIV IN SUMOylation mutations did not affect subcellular localization or viral DNA nuclear import . Therefore, conclusive biochemical and functional data are still elusive in terms of the impacts of IN SUMOylation during HIV-1 viral replication.
SUMOs can also noncovalently interact with other proteins through specific SUMO-interacting motifs (SIMs). The most well characterized SIM is V/I-x-V/I-V/I or V/I-V/I-x-V/I/L, where x can be any amino acid in a parallel or anti-parallel orientation [34, 35, 36]. SUMO-modified proteins can interact with SIM-containing binding partners through noncovalent binding. Notable examples include the SIMs of human TRIM5α, which bind to SUMO-conjugated capsid protein and restrict M-MLV infection , and RanBP2 SIM mediates its binding with the complex of RanGAP1/SUMO1 and Ubc9 . Overall, the functional consequences of the SUMO-SIM interaction vary considerably in different protein contexts, affecting protein SUMOylation, protein localization, and protein-protein interactions. (see a review ).
Interestingly, IN was shown to interact with SUMO1 and SUMO2 in a yeast two-hybrid system and a coimmunoprecipitation (co-IP) assay . Thus, the intriguing questions to ask are whether IN bears SIMs and how the INSIM-SUMO interaction modulates the multiprotein complex formation among IN and its SUMOylated cellular cofactors to affect different functions of IN. In this study, we examined the amino acid sequence of IN and defined two functional SIMs (200IVDI203 and 257IKVV260) in the catalytic core domain (CCD) and C-terminus. The SIMs of IN were shown to negatively regulate SUMOylation of IN, differentially modulate the IN-LEDGF/p75 and IN-Ku70 interactions, and contribute to the nuclear translocation step of HIV-1 IN. These findings not only uncover two possible SIMs of IN but also provide novel mechanistic insights into the regulation of multiple functions of IN by SIMs.
Cell lines and transfection
Human embryonic kidney 293 T and HeLa cell lines were cultured in Dulbecco’s Modified Eagle Medium (DMEM) supplemented with 10% fetal bovin serum (FBS) and 1% penicillin-streptomycin. Human CD4+ C8166 T-lymphoid cells were maintained in RPMI-1640 medium supplemented with 10% FBS and 1% penicillin-streptomycin. For the transfection of 293 T cells and HeLa cells, the standard calcium phosphate precipitation technique was used, as described previously  .
To enhance the HIV IN expression, we have generated and used the codon-optimized IN pAcGFP-INopt plasmid in the study, which has been described elsewhere . The constructs of GFP-INopt mutants M1 (V72A/I73A), M2 (I200A/V201A), M3 (V259A/V260A), M1 + M2 (V72A/I73A/I200A/V201A), M1 + M3 (V72A/I73A/V259A/V260A) and M2 + M3 (I200A/V201A/V259A/V260A) were synthesized through a two-step based PCR method using the GFP-INopt as a template and cloned into pAcGFP-C vector (Clontech) at BglII and EcoR1 sites . The following primers were used for constructing various IN SIM mutants: 5′-IN-BglII primer: (5-TAAGATCTTCCTGGACGGCA-3) and 3′- IN-EcoR1 primer (5-GCTGAATTCTCAGTCCTCGTCCT-3); 5′-IN 72,3AA primer (5-AGGGAAAGGCTGCACTAGTGGCAGTG-3) and 3′-IN 72,3AA primer (5-CACTGCCACTAGTGCAGCCTTTCCCT-3); 5′-IN 200,1AA primer (5-AGGAGAGAGGGCAGCTGACATCATC-3) and 3′-IN 200,1AA (5-GATGATGTCAGCTGCCCTCTCTCCT-3); 5′-IN 259,60AA primer (5-AGCGACATCAAT GCAGCTCCTAGGCGGAAGG-3) and 3′-IN259,60AA primer (5-CCTTCCGCCTAGGAGCTGCATTGATGTCGCT-3). The IN 3KR mutant (K46R/K136R/K244R) and 3VI mutant (V72A/I73A, I200A/V201A, V259A/V260A) had been synthesized and cloned into the pUC57 vector by GenScript Inc. Then the IN 3KR or 3VI fragment was excised from pUC57-INopt with BamHI and cloned in frame at the 3′ end of the pAcGFP1-C vector with the same restriction enzyme. All the mutants were confirmed by sequencing.
SRa-HA-SUMO2 (plasmid 17,360) and pcDNA3/HA-SUMO3 (plasmid 17,361) were kindly provided by Dr. Edward Yeh from Addgene . The pcDNA3-V5-Ubc9 was a generous gift from Dr. Ronald Hay (University of St. Andrews, St. Andrews, UK). The full-length wild-type Ubc9 was cut by BamH1/XhoI sites from pcDNA3-V5-Ubc9 and then cloned into CMV-HA vector. The constructed plasmid was named HA-Ubc9. SVCMVin-T7-LEDGF, and SVCMV-T7-Ku70 have been described previously [8, 19]. To construct pProLabel-Ku70, SVCMV-T7-Ku70 was digested with BamH1/Not1 and inserted into vector pProLabel which is derived from pProLabel-LEDGF .
HIV-1 HxBru RT/IN defective proviral plasmid (BruΔRI/R−/Gluc) used in this study was modified from a previously described Bru ΔRI/R- provirus . To investigate the effect of IN SIM mutants on viral replication, mutant M2 (I200A/V201A) or M3 (V259A/V260A) was introduced into CMV-RT-IN express plasmid as described before .
Antibodies and reagents
The rabbit anti-GFP polyclonal antibody (Molecular Probes Inc.) was used for immunoprecipitation. The antibodies for Western Blot (WB) were as follows: mouse anti-Ku70 (Abcam), horseradish peroxidase (HRP)-conjugated anti-GFP antibody (Molecular Probes), HRP-conjugated anti-HA antibody (Miltenyi Biotec.), and HRP-conjugated anti-T7 antibody (Novagen). The secondary antibody sheep anti-mouse IgG was purchased from Amersham Biosciences.
Co-immunoprecipitation assay (co-IP)
The protocol for the co-immunoprecipitation assay studying the interaction between HIV-1 GFP-INwt/mut with HA-SUMO3/2 proteins was essentially as described , with minor modifications. Briefly, the cells after 40 h transfection were collected and washed with cold Phosphate buffered saline (PBS) once and then lysed in lysis buffer (20 mM Tris-HCl pH 7.5, 100 mM NaCl, 0.5% NP-40, 0.5 mM EDTA, 0.5 mM PMSF and protease inhibitor cocktail) on ice for 20 min. After centrifugation for 20 min at 14,000RPM to remove the cell debris, the cell lysates were precleared with protein G-Sepharose for 2 h, rotated with anti-HA mouse antibody at 4 °C for 3 h followed incubated with protein A sepharose overnight. The immunoprecipitates were washed with lysis buffer five times, and the bound proteins were separated in 12% SDS-PAGE gel and immunoblotted with anti-GFP antibody to detect HA-SUMO3/2-bound GFP-INwt/mut. 2% of the total celllysats were detected for the expressions of GFP-INwt/mut and HA-SUMO3/2.
The interactions between IN and various cellular proteins including T7-LEDGF/p75, T7-Ku70 or pProlabel-Ku70 and HA-Ubc9 were verified by co-IP as described above. Briefly, cell lysates from 293 T cells co-transfected GFP-IN and T7-LEDGF/p75, T7-Ku70, pProlabel-Ku70 or HA-Ubc9 were immunoprecipited with rabbit anti-GFP antibody. The IN-bound proteins were detected by a WB using anti-T7 or anti-HA antibody, or measured for ProLabel activity using the POLARstar OPTIMA multidetection microplate reader (BMG Labtech, Ortenberg, Germany)  (chemiluminescent co-IP system).Two percent of transfected cell lysates were used to detect the expressions of different proteins by WB using corresponding antibodies.
Detection of IN SUMOylation using immunoprecipitation analysis (SUMOylation assay) was described previously  with minor modifications. Two hundred and ninety-three T cells were cotransfected with HA-SUMO3 and GFP-IN wt/mut for 40 h. The cells were harvested and washed in cold PBS once and added 10 unit/ml Benzonase (Novagen, Billerica, MA, USA) in 2 mM MgCl2 for 20 min to reduce the cellular viscosity. Then the cells were lysed in 150 μl lysis buffer (0.15 M Tris-HCl, pH 6.7, 5% SDS, and 30% glycerol), which is then diluted 1:10 in PBS/0.5% NP40 plus complete protease inhibitor (Roche). Cell lysates were incubated with rabbit anti-GFP antibody for 2 h and followed by the protein A-Sepharose for another 2 h at 4 °C. The bound proteins were eluted with 4x Laemmli buffer and separated on SDS-PAGE gel. SUMO conjugated IN was detected by mouse anti-HA antibody in WB.
HeLa cells were grown on glass cover slips (12 mm2) in 24-well plates for 24 h and then transfected with different GFP-IN plasmids. After 48 h, cells on the cover slip were fixed and permeabilized for 30 min in methanol/acetone (1:1 ratio) at room temperature. The glass cover slips were incubated with a primary rabbit anti-GFP antibody followed by a secondary FITC-conjugated anti-rabbit antibody. Nuclei were stained with DAPI. Cells were visualized on a Carl Zeiss microscope (Axiovert 200) with a 63x oil immersion objective.
Subcellular protein fractionation
Two hundred and ninety-three T cells were transfected with AcGFP-IN wt or 3VI in 6-well plate for 48 h. Cells were harvested and proteins were sequentially extracted, yielding cytoplasmic, nuclear and chromatin-bound fractions using a Thermo Scientific Subcellular Protein Fractionation Kit (Thermo Scientific, USA). Each fraction of proteins was subject to WB analysis using the anti-GFP antibody.
Single cycle viral replication and infection
A HIV-1 single-cycle replicating virus was produced in 293 T cells as described previously . Briefly, 293 T cells were co-transfected with an RT/IN /deleted HIV-1 provirus Bru∆RI/Gluc and each CMV-Vpr-RT-IN (wt or SIM M2 and M3 mutant) expression plasmid. After 48 h post-transfection, viruses were collected and concentrated from the supernatants by ultracentrifugation at 35,000 rpm for 2 h. Virus titers were quantified using HIV-1 p24 Antigen Capture Assay Kit (purchased from the NCI-Frederick AIDS Vaccine Program).
To test the effect of the IN mutants on viral infection, equal amounts of single cycle replicating viruses (adjusted by virion-associated p24 levels) were used to infect C8166 T cells 2 h, then washed and cells were cultured at 37 °C. At different time points after infection, the supernatant from each sample supernatants were collected and used for Gaussia luciferase Assay and HIV-1 p24 assay as described previously .
Real-time quantitative PCR analysis
C8166 T cells were infected with above single cycle replicating virus harboring wild-type IN or IN SIM mutants. Heat-inactivated virus (pretreated at 65° for 30 min) was used as a negative control. 2 h after infection, the cells were washed twice and cultured in complete RPMI. At 12, 24 and 48 h post-infection, 1 × 106 infected cells were harvested and subjected to DNA isolation using QIAmp blood DNA minikit (Qiagen). The total HIV-1 DNA, 2-LTR circle and integrated DNA levels were quantified in Mx3000P real-time PCR system (Stratagen, CA), with the protocols described previously .
HIV-1 IN contains two SIMs required for efficient binding to SUMO3
HIV IN SIM mutants decrease its own SUMOylation and Ubc9 binding
Since the SUMO E2-conjugating enzyme Ubc9 is indispensable for the SUMOylation of all proteins, and HIV-1 IN was shown to interact with Ubc9 in a previous study , we next tested whether IN/SUMO binding via SIMs has any effect on the IN/Ubc9 interaction, thus negatively regulating the SUMO conjugation of IN. We assessed the interaction between HA-Ubc9 and the GFP-INwt or 3VI mutant using cell-based co-IP assays . The data revealed that the GFP-IN3VI mutant had greatly increased IN/Ubc9 binding when compared with GFP-INwt (Fig. 3c, upper panel, compare lane 3 with lane 2). The increased binding ability of GFP-IN3VI with HA-Ubc9 is consistent with the increased SUMOylation level of 3VI (Fig. 3b, lane 4). Above observation suggest that IN-SUMO noncovalent binding through its SIMs disfavors its own SUMOylation.
IN SIMs differentially regulate IN-LEDGF/p75 and IN/Ku70 interactions
Ku70 is another IN-interacting protein that is subject to SUMO modification , we next analyzed the effect of SIM in IN on the IN-Ku70 interaction. Briefly, a plasmid expressing GFP-INwt, 3KR, or 3VI was cotransfected with T7-Ku70 (Fig. 4a)  in 293 T cells. The interaction of IN-Ku70 was first verified by the co-IP assay. The results showed that the IN mutant 3KR and INwt displayed similar binding to T7-Ku70, whereas the IN mutant 3VI had two-fold increased binding affinity for Ku70 (Fig. 4c left panel). Additionally, above observation was confirmed by using chemiluminescent co-IP system, as described previously . Briefly, GFP-INwt, 3KR, or 3VI was cotransfected with ProLabel-Ku70 in 293 T cells. The interaction of IN-Ku70 was verified by chemiluminescent co-IP assay as described in the Materials and Methods. Consistent with the above observation, the experiment confirmed that IN mutant 3KR and INwt bind PL-Ku70 with similar binding affinities, whereas the 3VI mutant had an increased binding affinity for Ku70 (Fig. 4c middle panel), even though similar expression levels of GFP-INwt and mutants 3KR and 3VI were detected in the cells (Fig. 4c right panel). These results indicate that IN SIMs differentially regulate IN-LEDGF/p75 and IN-Ku70 binding.
IN SIMs influence the intracellular localization of the IN protein
HIV-1 bearing IN SIM mutations is defective at the early steps of replication
To further define which step(s) of the HIV-1 replication cycle were affected, we analyzed viral reverse transcription, nuclear import and integration steps in C8166 T cells infected with IN SIM mutant viruses by real-time PCR. The results showed that the viral cDNA synthesis in HIV-1 M2 and M3 mutant virus-infected cells were decreased to 2- and 3-fold, respectively, compared to that of wild-type virus infected cells (Fig. 6d). Moreover, the levels of 2-LTR circles in M2 and M3 mutant virus-infected C8166 cells were approximately 4- and 11-fold lower, respectively, than that of the wild-type virus (Fig. 6e). As expected, the integrated proviral DNA could not be detected in either M2 or M3 virus-infected samples (Fig. 6f), which is well correlated with the replication defects of M2 or M3 mutant virus. All of these data suggest that the SIMs present in HIV IN are required for the early establishment of viral infection, including reverse transcription, nuclear import, and integration.
In this study, we report that HIV-1 IN bears two functional SIMs (SIM2 200IVDI203 and SIM3 257IKVV260), that negatively regulate the SUMOylation of IN, as well as the interaction between IN and SUMO E2 conjugation enzyme Ubc9. Also. The results indicate that SIMs in IN are required for its interaction with LEDGF/p75, but not with Ku70. Viruses carrying IN SIM mutants showed impaired viral reverse transcription, nuclear import and integration steps, resulting in defective replication. This report provides the first evidence for the roles of noncovalent SIMs in HIV IN for its functions during viral replication.
Sequence analysis revealed that the three putative SIMs (SIM1 72VILV75, SIM2 200IVDI203 and SIM3 257IKVV260) present in IN conform to this consensus (Fig. 1b). However, our mutational analysis suggests that SIM2 and SIM3 present the major sites for the IN-SUMO interaction. Within these two IN sequences, the hydrophobic residue I200 is implicated in both chromatin and LEDGF/p75 binding ; V260 is involved in the multimerization and structural stabilization of IN [52, 53]. In this study, the SIM2 mutant I200A/V201A had decreased IN-LEDGF/p75 binding affinity (Fig. 4b), which is consistent with a previous report . However, it remains an open question as to whether the INSIM-SUMO interaction has any impact on its chromatin association or multimerization. Remarkably, V201I, the mutant sequence that still conforms to the consensus SIM, occurs as a natural polymorphism in drug-naïve patients [54, 55]. This conservative substitution within SIM2 200IVDI203 thus highlights the importance of this sequence in the functions of IN and HIV-1 replication.
Noncovalent SUMO binding or the SIM-SUMO interaction has been shown to facilitate SUMOylation of SIM-containing proteins [50, 56, 57, 58]. For example, the interaction between the SIM of Sp100 and SUMO-Ubc9 enhanced the SUMOylation of Sp100 . This SIM-dependent SUMOylation has also been described in various SUMO targets, such as Daxx, RANBP2/Nup358, HIPK2 and BLM [50, 57, 58]. Interestingly, our results also showed that the IN SIM mutant 3VI has increased SUMOylation levels compared with INwt, suggesting that IN SIMs negatively regulate SUMOylation (Fig. 3b). Another line of evidence from this study also strongly supports this conclusion. The mutant 3VI had significantly increased Ubc9 binding ability compared with INwt (Fig. 3c). Ubc9 directly binds the SUMO conjugation consensus ψ-K-x-D/E sequence in substrates [59, 60], and mutating ψ-K-x-D/E abolishes both Ubc9 binding and the SUMOylation of substrate proteins . Similarly, a previous study reported that Srs2 SUMOylation inhibits its noncovalent SUMO binding, possibly due to the reduced availability of its SIM motif for interactions with SUMOylated proteins in general by Srs2 SUMOylation . Thus, it appears that noncovalent SUMO binding and covalent SUMO modification or SUMOylation can mutually regulate with each other, either positively or negatively.
The functional outcomes for noncovalent SIM/SUMO binding vary and are largely dependent on SUMOylated proteins and SIM-containing binding partners. SUMO binding through SIM(s) affects protein stability, cytosolic-nuclear translocation, and transcriptional regulation through altered protein-protein or protein-DNA interactions at the molecular level (see a review ). To investigate whether the INSIM-SUMO interaction could mediate the binding of IN with its SUMOylated cellular cofactors, we tested the interactions between HIV-1 IN with two SUMOylated proteins, LEDGF/p75 and Ku70. Our data found that while the IN SIM mutant 3VI was severely impaired in IN-LEDGF/p75 binding, it showed a two-fold increase in IN-Ku70 binding affinity (Fig. 4b and c). Additionally, 3VI bound Nup62, a non-SUMOylated cofactor of IN , at the same level as INwt (data not shown). These results together imply that IN SIMs might be involved in the regulation of the interaction between IN and SUMO-conjugated binding partners. Closer examination revealed that the SIM1 mutant M1, which still binds SUMO3, retains the full ability to interact with LEDGF/p75 (Fig. 4b). This observation thus strengthens the notion that SIM2 and SIM3 of IN are required for the IN-LEDGF/p75 interaction. However, we cannot formally exclude the possibility that creating six point mutations in 3VI might have profound impacts on other functions of IN, which may indirectly influence the IN-LEDGF/p75 or IN-Ku70 interaction. For example, V260 has been shown to be critical for the multimerization of IN , and I200 is required for the chromatin binding ability of IN . The SIM-SUMO interaction has been shown to influence the subcellular localization of SIM-containing proteins. A prominent example is the sequestration of Daxx to PML nuclear bodies, which is mediated through the binding of the SIM located at the C-terminus of Daxx and SUMOylated PML . Another example is that the SIMs of PML, Sp100 and hDaxx are required for the recruitment of these proteins to herpes simplex virus type 1 (HSV-1)-induced foci, which also recruit SUMO proteins and SUMO E3 ligase PIAS2β . In the present study, our results from HeLa cells and 293 T cells revealed that the IN SIM mutant 3VI was severely impaired in its nuclear localization (Fig. 5a and b). More specifically, SIM2 200IVDI203 and SIM3 257IKII260 but not SIM1 72VILV75 are involved in the nuclear import of IN proteins (Fig. 5a). As both SIM2 and SIM3 mutants that do not exclusively localize to the nuclei are also impaired for IN-SUMO3 and IN-LEDGF/p75 interactions, and LEDGF/p75 was initially reported to be indispensable for the nuclear import and chromosomal targeting of IN [31, 33], the cytoplasmic localization pattern of SIM2 and SIM3 mutants might be the reason or result of impaired IN-LEDGF/p75 interaction and/or chromatin association. In accordance with this hypothesis, SIM2 mutant I200A was shown to be defective for chromatin binding in a previous report . Second, we also consider the possibility that mutations introduced to IN SIMs might block the recruitment of SUMOylated cellular cofactor(s) of IN, which is required for the nuclear translocation of IN proteins. RANBP2 (Nup358) is one of the candidates that is SUMOylated and might be involved in the nuclear import of IN. RANBP2 is a nucleoporin with SUMO E3 ligase activity that harbors both SIMs and SUMO conjugation sites [35, 57, 63, 64]. As an SUMO E3 ligase, this protein has been shown to promote the SUMOylation of a number of SUMO targets, including Mdm2, HDAC4, topoisomerase II-alpha, PML, or Sp100 [57, 65, 66, 67]. Additionally, RANBP2 has been shown to be critical for HIV-1 replication and is involved in the nuclear import of the PIC and integration, both of which are closely linked with the functions of the HIV-1 IN [68, 69]. We may speculate that SUMOylated proteins, such as RANBP2, might form a complex with IN through binding SIMs and function in the nuclear import of IN. This possibility requires further experimental investigation.
It is known that introducing numbers of IN mutations in the context of virus may cause pleiotropic effects during HIV-1 replication [1, 70]. In order to limit such pleiotropic effects, we have used a previously described single cycle replicating virus system, in which the viral reverse transcriptase and integrase were complemented in trans  (Fig. 6a). Through the analyses with this HIV single cycle replication system, it showed that two functional SIMs (SIM2 200IVDI203 and SIM3 257IKVV260) are required for the multiple steps, including reverse transcription, nuclear import, and integration, in the early stage of HIV infection (Fig. 6). These observations are well correlated with the fact of SIMs are important in regulation of its SUMOylation, interacting with LEDGF/p75, and its ability for the nuclear import. Indeed several previous studies shown that the disruption of HIV integrase binding to endogenous LEDGF can significantly interfere with the progeny virus infectiousness [71, 72]. Another study also reported that a compound, LEDGINs, which specifically inhibit IN interaction with LEDGF/p75, was able to disrupt virus assembly and lead to the large portion of progeny virions display aberrant morphogenesis . Whether the SIMs in the IN play similar roles during HIV morphogenesis still wait for more detailed studies.
In conclusion, our data show that IN SIMs (200IVDI203 and 257IKVV260) bind to SUMO-2 and SUMO-3, facilitating INSIM-SUMO interactions, and are involved in the regulation of their own SUMOylation, cofactor binding, and multiple steps during the early stage of HIV replication. Further studies are needed to elucidate the molecular basis of IN SIMs in the regulation of these multiple functions of IN.
We thank Dr. Edward Yeh for providing the plasmids SRa-HA-SUMO2 (Sentrin 3) (Addgene plasmid # 17360) and pcDNA3/HA-SUMO3 (Addgene plasmid # 17361) . We also thank Dr. Ronald Hay (University of St. Andrews, UK) for generously providing pcDNA3-V5-Ubc9. Y-F.Z and K.D.J are the recipients of scholarships from the Manitoba Health Research Council/Manitoba Institute of Child Health. X-J. Y is a recipient of the Manitoba Research Chair Award.
This study was supported by the Canadian Institute of Health Research (CIHR) HIV/AIDS Bridge Funding Biomed/Clinic stream (HBF-131553) and a CIHR/MHRC RPP grant (RPA-132176) to X-J.Y.
Availability of data and materials
The datasets analyzed in this study are available from the corresponding.
author upon reasonable request.
ZF and XY conceived and designed the experiments; ZF, KDJ, and ZA performed the experiments; and ZA, XQ, RCS and XY analyzed the data and wrote the paper. All authors read and approved the final manuscript.
Ethics approval and consent to participate
Consent for publication
The authors authorize the publication.
The authors declare that they have no competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
- 2.Tsurutani N, Kubo M, Maeda Y, Ohashi T, Yamamoto N, Kannagi M, et al. Identification of critical amino acid residues in human immunodeficiency virus type 1 IN required for efficient proviral DNA formation at steps prior to integration in dividing and nondividing cells. J Virol. 2000;74(10):4795–806.PubMedPubMedCentralCrossRefGoogle Scholar
- 27.Vandekerckhove L, Christ F, Van Maele B, De Rijck J, Gijsbers R, Van den Haute C, et al. Transient and stable knockdown of the integrase cofactor LEDGF/p75 reveals its role in the replication cycle of human immunodeficiency virus. J Virol. 2006;80(4):1886–96.PubMedPubMedCentralCrossRefGoogle Scholar
- 33.Llano M, Vanegas M, Fregoso O, Saenz D, Chung S, Peretz M, et al. LEDGF/p75 determines cellular trafficking of diverse lentiviral but not murine oncoretroviral integrase proteins and is a component of functional lentiviral preintegration complexes. J Virol. 2004;78(17):9524–37.PubMedPubMedCentralCrossRefGoogle Scholar
- 40.Yao XJ, Subbramanian RA, Rougeau N, Boisvert F, Bergeron D, Cohen EA. Mutagenic analysis of human immunodeficiency virus type 1 Vpr: role of a predicted N-terminal alpha-helical structure in Vpr nuclear localization and virion incorporation. J Virol. 1995;69(11):7032–44.PubMedPubMedCentralGoogle Scholar
- 54.Ceccherini-Silberstein F, Malet I, Fabeni L, Dimonte S, Svicher V, D'Arrigo R, et al. Specific HIV-1 integrase polymorphisms change their prevalence in untreated versus antiretroviral-treated HIV-1-infected patients, all naive to integrase inhibitors. J Antimicrob Chemother. 2010;65(11):2305–18.PubMedCrossRefGoogle Scholar
Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.